98%
921
2 minutes
20
Background: Lumbar spinal stenosis (LSS) is a common degenerative spinal condition that limits function due to reduced space for neurovascular structures. Traditional direct open lumbar decompression (DOLD) is the standard treatment after conservative measures fail. Recently, minimally invasive options such as percutaneous image-guided lumbar decompression (PILD), interspinous spacers (ISS), and interspinous fixation devices (ISFD) have gained popularity for moderate LSS without spinal instability.
Objective: This retrospective study evaluated the safety and efficacy of ISFD in patients with LSS treated at our center.
Patients And Methods: Data from 45 patients (26 males, 19 females) treated with ISFD between January 2023 and October 2024 were analyzed. Adverse events and pain outcomes were recorded using numerical rating scale (NRS) scores at baseline, 2 weeks, 1 month, and 3 months post-procedure.
Results: Only one minor complication was reported on the procedure day. procedure day. Mean NRS pain scores improved from 7.5 (baseline) to 3.5 (2 weeks), 3.0 (1 month), and 3.5 (3 months) (P < 0.001). At 2 weeks, 50% of patients had pain reductions ≥51%; at 1 month, 57.4% experienced ≥51% reduction; and by 3 months, 73% had more than 50% pain reduction (P < 0.001), indicating significant pain improvement over time.
Limitations: This was a single-center retrospective study with a small sample size and relatively short follow-up time.
Conclusion: ISFD appears to be a safe and effective minimally invasive treatment for LSS. Larger randomized controlled trials are needed to compare devices and refine procedural techniques.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399849 | PMC |
http://dx.doi.org/10.2147/JPR.S522987 | DOI Listing |
Stroke
September 2025
Department of Medicine, University of Melbourne, Parkville, Victoria, Australia. (V.Y., B.C.V.C., L.C., L.O., M.W.P.).
Background: To assess the efficacy and safety of tenecteplase in patients presenting within 24 hours of symptom onset with a large vessel occlusion and target mismatch on perfusion computed tomography.
Methods: ETERNAL-LVO was a prospective, randomized, open-label, blinded end point, phase 3, superiority trial where adult participants with a large vessel occlusion, presenting within 24 hours of onset with salvageable tissue on computed tomography perfusion, were randomized to tenecteplase 0.25 mg/kg or standard care across 11 primary and comprehensive stroke centers in Australia.
Circulation
September 2025
Division of Cardiology, Columbia University Irving Medical Center, New York, NY (S.A.P.).
Background: Limited treatment options exist for infrapopliteal disease in patients with chronic limb-threatening ischemia (CLTI), a condition associated with a high risk of limb loss. Interventional management of diseased infrapopliteal vessels with percutaneous transluminal angioplasty (PTA) is associated with high rates of restenosis and reintervention. In the LIFE-BTK trial, the drug-eluting resorbable scaffold (DRS) demonstrated superior 12-month efficacy compared with PTA in a selected CLTI population with predominantly noncomplex, mildly to moderately calcified lesions.
View Article and Find Full Text PDFRetin Cases Brief Rep
October 2024
Eye Clinic, Humanitas-Gradenigo Hospital, Torino, Italy.
Purpose: To study the efficacy and safety of pro re nata regimen of brolucizumab, without loading dose, in treatment-naive patients with neovascular age-related macular degeneration (nAMD).
Case Series: Retrospective, observational study. We included all consecutive patients diagnosed with treatment- naïve nAMD undergoing Brolucizumab in Humanitas eye clinic, Turin, Italy between April 2022 and May 2023.
Int J Gen Med
September 2025
Department of Pediatric, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin, 130000, People's Republic of China.
Background: Mycoplasma pneumoniae pneumonia (MPP) is a common respiratory infection in children, current treatments are limited by resistance and side effects. This study aims to evaluate the clinical efficacy and safety of combining Qingke Mixture with azithromycin for treating MPP in children.
Methods: This prospective, randomized, double-blind, controlled trial included 92 children diagnosed with MPP.
Mol Ther Methods Clin Dev
June 2025
Precision Safety, Pharma Product Development, Roche Innovation Center Basel, CH-4070 Basel, Switzerland.
Adeno-associated virus (AAV) vectors are widely used in gene therapy, particularly for liver-targeted treatments. However, predicting human-specific outcomes, such as transduction efficiency and hepatotoxicity, remains challenging. Reliable models are urgently needed to bridge the gap between preclinical studies and clinical applications.
View Article and Find Full Text PDF